M/s. Ranbaxy Farmaceutica Ltda :

M/s. Ranbaxy Farmaceutica Ltda is a Brazilian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations. Established on November 4, 1993, the company is headquartered in Rio de Janeiro, Brazil. It operates under the legal entity CNPJ 73.663.650/0001-90, with a registered capital of R$ 17,366,900.00. (cnpj.ohub.com.br) The company is a subsidiary of Sun Pharma (Netherlands) B.V. and Ranbaxy Holdings UK Limited, both of which are foreign entities. (cnpj.ohub.com.br) Ranbaxy Farmaceutica Ltda plays a significant role in Brazil's pharmaceutical distribution network, serving as a key importer of generic medicines and contributing to the availability of affordable healthcare solutions across the country.

While specific details about M/s. Ranbaxy Farmaceutica Ltda's warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established distribution network within Brazil. The company has been involved in numerous shipments, primarily sourcing products from India, indicating a robust logistics framework capable of handling international trade efficiently. This network likely encompasses multiple distribution centers strategically located to ensure timely delivery of pharmaceutical products to various regions within Brazil.

M/s. Ranbaxy Farmaceutica Ltda functions as a primary wholesaler in Brazil's pharmaceutical supply chain. By importing and distributing finished pharmaceutical formulations, the company bridges the gap between international manufacturers and the Brazilian market, ensuring the availability of essential medications. Its focus on generic medicines aligns with Brazil's healthcare objectives of providing cost-effective treatment options to the population. The company's operations are integral to the pharmaceutical distribution landscape, facilitating access to a wide range of therapeutic products.

M/s. Ranbaxy Farmaceutica Ltda exhibits a high degree of sourcing concentration, with a total import value of $19.1 million USD from India over 433 shipments, primarily from a single supplier, Sun Pharmaceutical Industries Limited. This single-source dependency indicates a strategic choice to maintain a consistent supply chain and potentially leverage favorable terms with a key supplier. However, such concentration also poses risks, including vulnerability to supply disruptions or changes in supplier dynamics. The stability of this relationship is crucial for the company's operations, and any shifts in the supplier's capacity or policies could significantly impact M/s. Ranbaxy Farmaceutica Ltda's ability to meet market demand.

The resilience of M/s. Ranbaxy Farmaceutica Ltda's supply chain is closely tied to its reliance on a single supplier, Sun Pharmaceutical Industries Limited. This dependency may limit the company's ability to diversify its sourcing options, potentially exposing it to risks associated with supply chain disruptions. The company's focus on a limited number of therapeutic categories and formulations further concentrates its supply chain. To enhance resilience, M/s. Ranbaxy Farmaceutica Ltda could consider diversifying its supplier base and expanding its product portfolio, thereby mitigating potential risks associated with over-reliance on a single source.

The sourcing pattern of M/s. Ranbaxy Farmaceutica Ltda, characterized by a concentrated supplier base and a focus on specific therapeutic categories, positions the company as a significant player in Brazil's pharmaceutical market. This strategy allows for streamlined operations and potential cost advantages. For Indian exporters, understanding this pattern presents an opportunity to strengthen relationships with M/s. Ranbaxy Farmaceutica Ltda by offering complementary products or services that align with the company's existing portfolio. Additionally, exploring avenues to diversify the company's supplier base could lead to more competitive pricing and enhanced supply chain stability.

In Brazil, the regulation of pharmaceutical products is overseen by the Brazilian Health Regulatory Agency, known as Anvisa (Agência Nacional de Vigilância Sanitária). Anvisa is responsible for the authorization of clinical trials, market authorization of drugs and biological products, and post-marketing surveillance. (gov.br) The agency classifies drugs into various categories, including new synthetic and semi-synthetic drugs, generic drugs, similar drugs (branded generics), and others, each subject to specific regulatory requirements. For Indian pharmaceutical exporters, understanding Anvisa's regulatory framework is essential for ensuring compliance and facilitating the market entry of their products into Brazil.

Import licensing in Brazil is governed by Anvisa, which requires pre-market approval ("registro") for pharmaceutical products considered to present the greatest health risks. This approval process ensures that imported drugs meet Brazilian sanitary regulations before commercialization. (gov.br) Good Manufacturing Practice (GMP) certification is also mandatory for pharmaceutical products imported into Brazil. Anvisa recognizes GMP certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the acceptance of international standards. Indian exporters should ensure that their manufacturing facilities hold valid GMP certifications recognized by Anvisa to comply with Brazilian import requirements.

Pharmaceutical products imported into Brazil must undergo batch testing to verify their quality and safety. Stability studies are required to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling requirements include providing information in Portuguese, the official language of Brazil, and adherence to specific formatting and content guidelines set by Anvisa. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. Indian exporters must ensure that their products meet these quality and labeling standards to gain approval for sale in Brazil.

Between 2024 and 2026, Anvisa implemented several policy changes affecting pharmaceutical imports into Brazil. These changes include updates to the pre-market approval process, adjustments in GMP certification requirements, and revisions to labeling and packaging standards. The agency has also introduced stricter post-marketing surveillance measures to monitor the safety and efficacy of imported drugs. Indian pharmaceutical exporters should stay informed about these regulatory updates to ensure ongoing compliance and facilitate the smooth entry of their products into the Brazilian market.

M/s. Ranbaxy Farmaceutica Ltda's focus on importing finished pharmaceutical formulations in the therapeutic categories of Central Nervous System (CNS) & Psychiatric, Cardiovascular, and Advanced Antibiotics indicates a strategic alignment with prevalent health concerns in Brazil. The significant import values in these categories suggest a strong market demand for treatments in these areas. By concentrating on these therapeutic segments, the company aims to address critical healthcare needs and capitalize on the substantial market opportunities they present.

M/s. Ranbaxy Farmaceutica Ltda's sourcing strategy is centered on importing generic drug formulations from India, with a particular emphasis on specific therapeutic categories. The company's preference for finished pharmaceutical formulations over raw Active Pharmaceutical Ingredients (APIs) indicates a focus on ready-to-market products that can be distributed efficiently within Brazil. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages, aligning with the company's objective to provide affordable healthcare solutions to the Brazilian market.

Based on its product mix, M/s. Ranbaxy Farmaceutica Ltda serves the wholesale distribution segment of the Brazilian pharmaceutical market. By importing and distributing a range of generic medications, the company supplies products to various stakeholders, including retail pharmacies, hospitals, and healthcare providers. Its focus on high-demand therapeutic categories positions it as a key player in meeting the healthcare needs of the Brazilian population.

There is a realistic opportunity for new Indian suppliers to engage with M/s. Ranbaxy Farmaceutica Ltda, particularly in the therapeutic categories where the company has a significant import presence. By offering complementary products or expanding the existing product portfolio, Indian exporters can strengthen their partnership with the company. Additionally, addressing any gaps in the company's current sourcing strategy, such as diversifying the supplier base or introducing innovative formulations, could enhance the resilience and competitiveness of M/s. Ranbaxy Farmaceutica Ltda's supply chain.

Indian exporters aiming to supply M/s. Ranbaxy Farmaceutica Ltda and the broader Brazilian market must ensure compliance with Anvisa's regulatory requirements. This includes obtaining pre-market approval for pharmaceutical products, holding GMP certifications recognized by Anvisa, and adhering to labeling and packaging standards. Additionally, maintaining a robust quality assurance system and staying informed about regulatory updates are essential to meet the expectations of Brazilian importers and regulatory authorities.

To establish a relationship with M/s. Ranbaxy Farmaceutica Ltda, Indian exporters should initiate contact through formal channels, providing comprehensive product information and demonstrating compliance with Anvisa's regulatory standards. Participating in industry trade fairs and networking events in Brazil can also facilitate connections. Understanding the company's specific product needs and aligning offerings accordingly will enhance the potential for collaboration. It is advisable to